D-type cyclins are important cell cycle regulators that promote cellular proliferation in response to growth factors by inactivation of the retinoblastoma protein (Rb). Cyclin D1 has been shown to be overexpressed in several cancer types and to act as an oncogene in breast cancers. As D-type cyclins are rate limiting for progression into S phase, the level at which they accumulate must be carefully regulated. Several mechanisms leading to overexpression of cyclin D1 have been reported including ampli®cation, translocation and stabilization of the mRNA. Here, we present data showing elevated cyclin D1 protein in breast cancer samples in the absence of elevated mRNA level. Further, we found that in these cases, cyclin D3 protein also accumulates and that the coordinate increase in cyclin D1 and D3 occurs in 15% (7/47) of breast cancers. In addition we show that blocking the activity of the 26S proteosome results in the accumulation of cyclin D1 and D3, that both D-type cyclins are ubiquitinated and associate with Cul-1, a component of the SCF ubiquitin ligase complex. Finally, we show that the coordinated elevation of cyclin D1 and D3 is also observed in the breast cell line MCF-7 and demonstrate that the degradation of cyclin D1 and D3 is de®cient in this cell line. These results indicate that cyclin D1 and cyclin D3 share a common mechanism of degradation and we propose that the coordinate increase of D-type cyclins observed in primary breast cancers re¯ects a defect in their proteolysis.
Introduction
The cyclin dependent kinases (cdk) are a family of serine/threonine protein kinases that control cell cycle progression through association with their regulatory subunits, known as cyclins. The assembly of speci®c cyclin-cdk complexes in various phases of the cell cycle leads to the phosphorylation of substrates, which trigger progression from one phase of the cycle to the next. One of the best described examples of such a mechanism is the phosphorylation of the Retinoblastoma (Rb) protein in response to extracellular signals (for a review, Weinberg, 1995) . Rb forms a complex with the E2F family of transcription factors and represses their activity. In the G1 phase, mitogenic signals are transduced to the cell cycle machinery by stimulating D-type cyclin transcription. Newly synthesized D-type cyclins associate with cdk4 and 6 and phosphorylate Rb. Cyclin E also contributes to the phosphorylation of Rb (Lundberg and Weinberg, 1998) . Hyperphosphorylation of Rb results in the release of E2Fs, which then regulate transcription of genes required for DNA replication (for a review, Helin, 1998) .
Cyclin D1 was independently discovered for its role: (i) as a mammalian cDNA able to complement a yeast strain de®cient in G1 cyclins (Xiong et al., 1991) ; (ii) as a gene upregulated in macrophages following exposure to colony stimulated factor (CSF-1) (Matsushime et al., 1991) ; (iii) as the potential bcl-1 oncogene, on chromosome 11q13 which is rearranged in parathyroid cancers (Motokura et al., 1991) . Mammalian cells contain three D-type cyclins D1, D2 and D3 which apparently have non-overlapping functions (Kato and Sherr, 1993) . They dier in their cdk association (Sweeney et al., 1997) and are expressed in various combinations in dierent tissues (Inaba et al., 1992) . Constitutive expression of all three D-type cyclins in the appropriate cell lines leads to shortening of G1 phase (Musgrove et al., 1994; Ando et al., 1993) indicating that D-type cyclins are rate limiting for cell cycle commitment and progression into S phase. However, accumulation of cyclin D1 in senescent ®broblasts contributes to cell cycle arrest by forming an inactive complex with cdk2 (Dulic et al., 1993) . Therefore, accumulation of D-type cyclins may have opposite eects in proliferating and non-proliferating cells. In addition, in neuronal cells, moderate expression of cyclin D1 causes growth stimulation while overexpression results in apoptotic cell death (Kranenburg et al., 1996) . These observations indicate that the net eect of cyclin D overexpression will depend on the proliferation status and level of overexpression in a particular cell type.
The level at which D-type cyclins accumulate is determined by the balance between the rates of synthesis and degradation. Until recently, most studies have focused on the transcriptional regulation of Dtype cyclins (Brooks et al., 1996; Phillip et al., 1994; Rao and Kohtz, 1995; Herber et al., 1994; Watanabe et al., 1998) . The ras pathway regulates transcription of cyclin D1 and provides the link between mitogenic signalling and induction of cyclin D1 (Albanese et al., 1995) . However, very little is known about the control of D-type cyclin degradation. Recently the ubiquitin-dependent pathway of proteolysis was shown to regulate the rapid turnover of cyclin D1 (Diehl et al., 1997) . Linkage of ubiquitin to the cyclin is a highly organized process involving the sequential action of an ubiquitin-activating enzyme (E1), an ubiquitin-conjugating enzyme (E2) and an ubiquitin-ligase (E3). This results in the targeting of the cyclin for degradation by the 26S proteosome. In Saccharomyces cerevisiae, the E2 is encoded by Cdc34 and associated with the E3, which is composed of three proteins: Skp1, a cullin (Cdc53) and an F-box protein (Grr1), collectively known as the SCF Grr1 complex (for a review, Krek, 1998) . Components of the SCF complex are conserved in humans (Lisztwan et al., 1998) but the direct involvement of this proteolytic machinery in D-type cyclin degradation in mammals has not been demonstrated.
Overexpression of cyclin D1 has been reported in several cancer types. Mechanisms leading to overexpression include, ampli®cation of chromosome 11q13 in breast and other cancers (Lammie and Peters, 1991; Motokura and Arnold, 1993) , translocation in B cell lymphoma (Motokura and Arnold, 1993; Rosenberg et al., 1991; Withers et al., 1991) , intrachromosomal inversion in parathyroid adenomas (Motokura et al., 1991) and mRNA stabilization (Lebwohl et al., 1994) . Overexpression of cyclin D1 in mouse mammary glands induce carcinomas (Wang et al., 1994) . In contrast, overexpression of cyclin D1 in B or T cells does not result in lymphoma but higher levels of cyclin D1 can accelerate lymphomagenesis induced by c-myc (Bodrug et al., 1994) . Interestingly, cyclin D1 has been shown to interact with the estrogen receptor in a cdk independent manner (Zwijsen et al., 1997; Neuman et al., 1997) . Therefore the oncogenic eect of cyclin D1 varies between tissues and its eect is potentially augmented by the presence of the estrogen receptor, although this issue has not been directly addressed.
While ampli®cation of the cyclin D1 gene has been observed in only 16% of breast cancers, immunostaining of paran embedded sections revealed up to 35% of breast cancers show accumulation of this protein (Gillett et al., 1994) . As proteolysis is an essential mechanism restricting D-type cyclins accumulation, we hypothesized that a defect in the degradation of cyclin D might also contribute to this discrepancy. We present data showing elevated cyclin D1 protein in the absence of elevated mRNA. Further, we found that in these cases cyclin D3 protein also accumulates and that the coordinated increase in cyclin D1 and D3 is present in 15% of breast cancers. Finally, we show that cyclin D1 and D3 degradation is mediated by the ubiquitin pathway of proteolysis, that they associate with a component of the SCF complex and that their degradation is signi®cantly reduced in the breast cell line MCF-7. We propose that the coordinated increase of D-type cyclins re¯ects a defect in their proteolysis.
Results
Elevated level of cyclin D1 protein in absence of increased levels of mRNA Previous studies have reported a lack of correlation between (i) cyclin D1 mRNA levels and gene ampli®cation (Buckley et al., 1993) and (ii) mRNA and protein levels (Gillett et al., 1994) . Elevated levels of mRNA observed in the absence of gene amplification may be explained by inversion of cyclin D1 gene which links it to an active promoter or stabilization of the mRNA. However, these mechanisms cannot explain the elevated protein levels in the absence of elevated mRNA observed in the latter study and it was suggested that either mRNA degradation or a mutation aecting cyclin D1 stability might account for this observation. To investigate further the correlation between cyclin D1 protein and mRNA levels we compared the level of cyclin D1 protein and mRNA in nine primary breast cancers. In some cases, elevated levels of cyclin D1 protein was associated with elevated levels of mRNA ( Figure 1a , cancers 1, 5 and 9). Conversely, a low level of cyclin D1 protein was re¯ected by a low level of mRNA ( Figure 1a , cancers 2, 6 and 8). Although in some cases, the dierence in protein and mRNA levels were dicult to interpret ( Figure 1a , cancers 4 and 7) and might simply re¯ect a dierence in loading, cancer 3 exhibited the most distinctive discrepancy as this cancer showed elevated cyclin D1 protein in presence of low level of mRNA. Figure 1 Comparison of cyclin D1 and cyclin D3 protein and mRNA level in primary breast cancers samples. (a) Thirty mg of total protein were resolved on a 12% SDS ± PAGE. Anti-cyclin D1 rabbit polyclonal antibody (M20) was used for immunoblotting. The membrane was stripped and reprobed with anti-actin mouse monoclonal antibody (N350). RT ± PCR analysis in primary breast cancers of cyclin D1 (top panel) and actin (lower panel). Cyclin D1 RT ± PCR products were analysed by Southern blotting. (b) The same Western blotting membrane used for detecting cyclin D1 was stripped and reprobed using the anticyclin D3 polyclonal antibody C-16. RT ± PCR analysis of cyclin D3 (top panel) and actin (lower panel). Cyclin D3 RT ± PCR products were analysed by Southern blotting
The integrity of the RNA in cancer 3 was con®rmed as the level of actin mRNA in this sample was identical to that observed in the other cancers ( Figure 1a) . Therefore, our results support the previous observation that in some cases cyclin D1 protein accumulates in primary breast cancer in absence of elevated levels of mRNA (Gillett et al., 1994) suggesting a posttranscriptional defect. However, the interpretation of our data is restricted by the limited quanti®cation obtained by RT ± PCR and Western analysis. To overcome this limitation, we investigated further the nature of the putative post-transcriptional defect.
A defect in proteolysis of cyclin D1 is a potential mechanism by which the accumulation of cyclin D1 protein would occur in absence of elevated level of mRNA. In Saccharomyces cerevisiae, mutations affecting the Cdc34-SCF Grr1 complex result in the coordinated stabilization of G1 cyclins by blocking their degradation by the 26S proteosome. Therefore, accumulation of more than one G1 cyclin is a hallmark for a proteolytic defect. As breast cancer cell lines expressed only cyclin D1 and D3, we next looked at the level of cyclin D3 protein in these cancers. We found a striking elevation in cyclin D3 protein in cancer 3 ( Figure 1b ). Cyclin D3 protein levels were very low in all other cancers. In contrast to the clear dierence in cyclin D3 protein level observed in cancer 3, cyclin D3 mRNA was not detectable, a feature of several other cancers ( Figure 1b) . Therefore, cancer 3 show elevated levels of both cyclin D1 and D3 proteins with normal level of mRNA in both cases. This coordinated accumulation of cyclin D1 and D3 in cancer 3 suggested a defect in proteolysis.
D-type cyclins accumulation is a speci®c defect
In humans several cullins and F-box proteins have been found, suggesting the existence of a large combination of SCF complexes. Until now, only one SCF complex in humans has been shown to be functionally conserved (Lisztwan et al., 1998) and is involved in the degradation of the transcription factor E2F-1 (A Marti and W Krek personal communication). The remarkable conservation of this complex from yeast to humans and its role in G1 cyclin degradation in yeast highlights an SCF complex as a strong candidate for the defect observed in cancer 3. As E2F-1 is a substrate for ubiquitination by an SCF complex in human, we examined whether there is also E2F-1 accumulation in cancer 3. Figure 2 shows that the level of E2F-1 was not increased in cancer 3 compared to either a cancer with elevated levels of cyclin D1 (cancer 1) or a cancer with low level of cyclin D1 and D3 (cancer 2). Therefore, mutations in the SCF complex targeting E2F-1 for degradation seem unlikely to be responsible for the defect leading to the cyclin D1 and D3 stabilization observed in this primary breast cancer.
Another important degradation machinery during the cell cycle is known as the anaphase promoting complex or APC (for a review, Murray, 1995) . The APC degrades mitotic cyclins and other proteins involved in sister chromatid cohesion (Imiger et al., 1995) . As in the case of the SCF, the APC is highly conserved from yeast to humans. We tested whether degradation of S phase and M phase cyclins was also aected in cancer 3. The level of cyclin A and cyclin B was found not to be elevated but rather lower compared to cancer 1 and 2. The signi®cance of the decreased levels of cyclin A and B is unknown but this result indicates clearly that the APC is active in this cancer. We conclude that the defect in cancer 3 does not aect either cyclin degradation in general or the degradation of E2F-1, suggesting that the defect is speci®c for D-type cyclins.
Coordinated accumulation of cyclin D1 and D3 is a frequent event in primary breast cancer
Our results suggest that in some cases, cyclin D1 and D3 proteins accumulate in absence of elevated levels of mRNA. However, this preliminary analysis is limited by the number of fresh primary breast cancers available and is therefore a poor indicator of the frequency of such event in breast cancer. To overcome this problem and determine the frequency at which D1 and D3 coordinated accumulation occurs in breast cancer, we analysed paran embedded breast cancers by immunohistochemistry. A total of 47 primary breast cancers were stained by immunohistochemistry using an antibody against cyclin D1. Staining patterns were scored according to the intensity and the percentage of stained cells (Figure 3 ). Out of a total of 47 cancers examined, 14 (30%) were found to be positive for cyclin D1 (Table 1) , which is in agreement with previous studies (Gillett et al., 1994) , and all 14 cancers were invasive. We pursued our immunohistochemical analysis to test whether cancers positive for cyclin D1 were also positive for cyclin D3. The 14 cancers that were positive for cyclin D1 were stained for cyclin D3 and 50% (7/14) were found to be positive for cyclin D3 as well (Table 1 and Figure 3 ). As strong immunostaining of cyclin D3 has been found to occur at a frequency of 10% in breast cancers (Bartkova et al., 1996) , the possibility exists that cyclin D3 and cyclin D1 overexpression occurs independently of each other. We reasoned that if this was the case, the same frequency of cyclin D3 staining would be expected to occur in cyclin D1 negative cancers. To test this hypothesis, 24 cyclin D1 negative cancers were stained for cyclin D3. Only one case was positive for cyclin D3 (Table 1) suggesting that cyclin D3 staining occurs at a frequency of 4% (1/24) in a population of cyclin D1 negative cancers compared to a frequency of 50% (7/ 14) in a cyclin D1 positive population. This result indicates a strong correlation between the overabundance of cyclin D3 and cyclin D1 in breast cancers. Therefore, this result con®rms and expands our preliminary observation made on fresh primary breast cancers and indicates that a coordinated accumulation of cyclin D1 and D3 accounts for an important subset of breast cancers.
Cyclin D1 and D3 are ubiquitinated
In mammalian cells, cyclin D1 protein has been shown to accumulate when the 26S proteosome is inhibited by All sections were stained with anti-cyclin D1 antibody (Upstate Biotechnology) and cyclin D3 antibody DCS-22 (Santa Cruz). Staining pattern were scored as described in Materials and methods the aldehyde inhibitor LLnL and to be ubiquitinated (Diehl et al., 1997) . Based on the coordinated regulation of G1 cyclin proteolysis in yeast, we examined whether blocking cyclin D1 degradation by inhibiting the 26S proteosome would also result in the coordinated increase in cyclin D3. Addition of LLnL led to the accumulation of cyclin D1 (Figure 4a ) as described previously (Diehl et al., 1997) . The same extract was analysed for cyclin D3 and we found that cyclin D3 also accumulates under these conditions ( Figure 4a ). As the 26S proteosome is involved in the degradation of a large number of proteins, the accumulation of cyclin D3 in presence of LLnL might result either from the inhibition of degradation of the ubiquitinated form of cyclin D3 or from an indirect eect on cellular metabolism. To distinguish between these possibilities, we tested whether cyclin D3 is ubiquitinated. Co-transfection of plasmids expressing cyclin D1 and an ubiquitin construct tagged with the Myc epitope resulted in the laddering of cyclin D1 protein, a hallmark of multi-ubiqutinated proteins ( Figure 4b ). This result con®rms the ubiquitination of cyclin D1 (Diehl et al., 1997) and that the presence of LLnL increases the accumulation of ubiquitinated intermediates. A similar experiment using cyclin D3 also resulted in the laddering of cyclin D3 (Figure 4b ). These results show that as for cyclin D1, cyclin D3 is ubiquitinated and degraded by the proteosome.
Cyclin D1 and D3 associate with the cullin, cul-1
We showed that cyclin D1 and D3 are both targeted for degradation by the ubiquitin pathway of proteolysis. However, the attachment of ubiquitin to a given protein can be achieved by several combinations of dierent ubiquitin conjugating (E2) and ubiquitin ligase (E3) complexes. In Saccharomyces cerevisiae, the SCF Grr1 complex provides the E3 activity for the ubiquitination of the G1 cyclins, Cln1 and Cln2 (for a review, Krek, 1998) . Further, Cdc53 a component of this complex, was identi®ed as a protein associated with Cln2 (Willems et al., 1996) . In humans, the homologue of Cdc53 is encoded by the Cul-1 gene (Kipreos et al., 1996) . Considering the conservation of the SCF component from yeast to humans, the role of this complex in G1 cyclin degradation in yeast and the association of Cdc53 with Cln2, we tested whether Cul-1 can associate with cyclin D1. U2OS cells were transfected with plasmids expressing HA tagged cyclin D1 and Cul-1 alone or in combination. Proteins were extracted, cyclin D1
HA immunoprecipitated using an anti-cyclin D1 antibody and Western blotting analysis performed using anti-HA antibody. As shown in Figure 5a , Cul-1 HA was coimmunoprecipitated with cyclin D1 HA . Immunoblotting of crude protein extracts indicated that transfection eciencies were similar in all cases (Figure 5b ). This result shows that as it was found for Cdc53 and Cln2 in yeast, in human Cul-1 and cyclin D1 can associate. This ®nding suggests that an SCF complex containing Cul-1 might be involved in cyclin D1 degradation.
To investigate whether cyclin D1 and cyclin D3 might be ubiquitinated by a common mechanism, we then looked whether Cul-1 can also associate with cyclin D3. As shown in Figure 5c and d, Cul-1 coimmunoprecipitates with cyclin D3 and this association was enhanced when the level of cyclin D3 was elevated by a short exposure to LLnL before protein extraction. This result suggests that both cyclin D1 and D3 are ubiquitinated by an SCF complex containing Cul-1. Further, this result supports the notion that a mutation aecting this complex would result in the coordinated accumulation of cyclin D1 and D3.
The breast cell line MCF-7 is defective in cyclin D1 and D3 proteolysis
Our results suggest strongly that a defect in proteolysis results in the coordinated accumulation of cyclin D1 and D3 in breast cancer. To test the hypothesis we next analysed by Western blotting the level of cyclin D1 and D3 in breast cancer cell lines. Two cell lines were used as control, the adenocarcinoma cell line U2OS which has been shown to rapidly degrade cyclin D1 (Diehl et al., 1997) and the uterine cell line SKUT-1B which has been shown to have a defect in the degradation of Figure 4 (a) Eect of the proteosome inhibitor LLnL on cyclin D1 and D3 levels. U2-OS cells were treated with DMSO alone (7) or with LLnL in DMSO (+) for 14 h. Total proteins were extracted and 30 mg run on a 12% SDS ± PAGE. Immunoblotting was performed using anti-cyclin D1 rabbit polyclonal antibody (M20) and with anti-cyclin D3 polyclonal antibody (C-16). The membrane was stripped and reprobed with anti-actin mouse monoclonal antibody (N350). (b) Ubiquitination of cyclin D1 and D3. U2OS cells were transfected with pCDNA3-cyclin D1 HA or pCDNA3-cyclin D3 plasmid alone or in combination with pCDNA3-ubiquitin MYC . Cyclin D1 HA or cyclin D3 were immunoprecipitated and resolved on a 7.5% SDS ± polyacrylamide gel. The immunoblot was probed using the anti-Myc antibody 9E10 to detect ubiquitination of cyclin D1 and D3 D-type cyclins (Welcker et al., 1996) . As predicted the levels of cyclin D1 and D3 were low in the U2OS cell line while these proteins were abundant in the SKUT-1B (Figure 6a ). Among the ®ve breast cell lines tested, cyclin D1 was abundant in the cell line ZR-75.1 as predicted due to an ampli®cation of the gene (Buckley et al., 1993) but the level of cyclin D3 was low in this cell line (Figure 6a) . However, the level of both cyclin D1 and D3 proteins were found to be elevated in the cell line MCF-7 (Figure 6a ). The level of cyclin D1 mRNA in MCF-7 has been reported to be elevated. We con®rm this observation as cyclin D1 mRNA levels are higher in this cell line compared to U2OS, however the level of cyclin D1 mRNA in the MCF-7 was much lower than in the ZR-75.1 cells (Figure 6b) . Further, cyclin D3 mRNA was similar in all three cell lines tested (Figure 6b ). These characteristics were reminiscent of cancer 3 (Figure 1 ). In addition, as observed in , ZR-75.1 and MCF-7 cells were subjected to pulse chase analysis as described in Materials and methods. Cyclin D1 and D3 were then immunoprecipitated at times indicated, labelled proteins were separated by SDS ± PAGE and visualized bȳ uorography cancer 3, the level of E2F-1 was not elevated in MCF-7 compared to U2OS and ZR-75.1 cells (data not shown). Considering that cyclin D1 and D3 share the same proteolytic machinery, we then tested by pulse chase analysis whether the turn-over of cyclin D1 and D3 was altered in the MCF-7 cells. In agreement with previous reports (Diehl et al., 1997; Welcker et al., 1996) the half-life of cyclin D1 is between 20 ± 30 min in the U2OS cells (Figure 6c ). This rapid turn-over was also observed in the breast cell line ZR-75.1 ( Figure  6c) . However, the half-life of cyclin D1 was increased to 80 ± 100 min in the MCF-7 cells (Figure 6c ). In agreement with the low level of cyclin D3 protein present in U2OS and ZR-75.1 cells (Figure 6a ), cyclin D3 was weakly detectable in the U2OS cells and below detectable levels in the ZR-75.1 cells. Nevertheless, the weak signal we obtained in the U2OS cells correlates with the previous report that the half-life of cyclin D3 range between 40 ± 50 min in these cells (Welcker et al., 1996) . In sharp contrast the half-life of cyclin D3 in MCF-7 cells was increased to 140 ± 160 min. The halflife of cyclin D1 and D3 were determined in three independent labelling experiments. Therefore, these results con®rm our hypothesis that the coordinated accumulation of cyclin D1 and D3 re¯ects a defect in proteolysis.
Discussion
Our results con®rm previous observations (Buckley et al., 1993; Gillett et al., 1994) that cyclin D1 protein levels do not always correlate with the level of mRNA, and that in some cases protein accumulation is observed in the absence of elevated mRNA levels. Further, our results indicate that in these cases cyclin D3 protein also accumulates in absence of elevated mRNA. In addition, we show that a large number of cyclin D1 positive cancers were positive for staining for cyclin D3 while cyclin D3 staining alone is rare. These observations suggest a common defect leading to the accumulation of cyclin D1 and D3 in these cancers. We have shown that cyclin D1 and D3 depend on the proteosome for their degradation, are both ubiquitinated and can associated with Cul-1. These results indicate that both cyclins are proteolysed by the same mechanism. Therefore, our data strongly supports a defect in proteolysis as the mechanism underlying the coordinated increase in D-type cyclin we observed in breast cancers. This hypothesis is supported by the observation that in the ovarian sarcoma cell lines SKUT1 and SKUT 1B defects in proteolysis eect simultaneously cyclin D1, cyclin D2 and D3 turnover (Welcker et al., 1996) . Further our results demonstrate that a defect in proteolysis is not unique to the SKUT1 and 1B cell lines but is also observed in the breast cancer cell line MCF-7.
In the MCF-7 cells, we observed a fourfold reduction in the turn-over of cyclin D1 and D3 indicating that D-type cyclin degradation, although defective in this cell line, is not completely abolished. This is consistent with the phenotype associated with the overexpression of cyclin D1 since massive accumulation leads to cell cycle arrest and apoptosis (Dulic et al., 1993; Kranenburg et al., 1996) while moderate accumulation accelerates the cell cycle (Musgrove et al., 1994; Ando et al., 1993) . It is therefore likely that such mechanism would lead to a selective pressure such that only mutations leading to a moderate reduction in the turn-over of D-type cyclins could arise.
The eect of cyclin D1 accumulation on breast cancer progression has been demonstrated in a trangenic mice model expressing cyclin D1 in mammary glands (Wang et al., 1994) . However, the eect of cyclin D3 on breast cancer development is unknown. The presence of cyclin D3 in a subset of cyclin D1 positive cancers raises intriguing questions concerning the potential amplifying role of cyclin D3 in those cancers. These issues are being investigated.
Another important question raised by our results is the nature of the proteolytic defect. The fact that E2F-1 does not accumulate in cancer 3 or in MCF-7 cells suggests that the defect lies in proteins, which are speci®cally involved in D-type cyclins degradation. Recently the mechanism for degradation of speci®c cell cycle regulators has been elucidated with the discovery of a family of speci®city factors known as F-box proteins (for a review, Krek, 1998) . Grr 1 is an F-box protein, which is required for degradation of G1 cyclins in yeast, while Cdc4 and Met 30 are F-box proteins required for the degradation of other proteins in yeast. Therefore in yeast at least three SCF complexes exist, the SCF Grr1 , SCF Cdc4 and SCF
Met30
. These SCF complexes dier only in the associated Fbox protein and target dierent proteins for degradation. In humans, the component of the SCF is conserved and many F-box proteins have been identi®ed. These observations suggest that in humans the SCF complexes targeting E2F-1 and D-type cyclins for degradation may contain dierent F-box proteins. Therefore, the F-box protein targeting D-type cyclins for proteolysis is a likely candidate for the defect observed in cancers which accumulate cyclin D1 and D3 but not E2F-1. A mutation in gsk3-beta is also a possibility as its activity is required for phosphorylation of cyclin D1, prior to cyclin D1 degradation (AJ Diehl and CJ Sherr, personal communication) . However, the involvement of this kinase in a variety of cellular pathways is harder to reconcile with a speci®c defect in D-type cyclin degradation. Further investigations are underway to test whether these cancers contain mutations in these genes.
Deregulated proteolysis of the CDK inhibitor p27 has been described in colorectal cancer (Loda et al., 1997) . In this case the degradation was shown to be increased rather than decreased as described in this study. However, it seems logical that in terms of cell cycle proteolysis, cancers could arise either by the stabilization of an oncogene, such as cyclin D1 or destabilization of a cancer suppressor gene such as p27 (Loda et al., 1997) or p53 (Schener et al., 1993) . Evidence for both of these processes has now been obtained.
Materials and methods

Cancer homogenization
Primary cancers used in this study were collected with patient consent and immediately frozen in liquid nitrogen following surgery. Cancers were ground to a ®ne powder in liquid nitrogen using a mortar and pestle and the resulting cancer homogenates were kept at 7708C.
Expression vectors and transfection
cDNA encoding the entire coding sequence of cyclin D1 HA , cyclin D3, Cul-1 HA and ubiquitin MYC were all expressed in mammalian cells using the pCDNA3 vector (Invitrogen). pCDNA3-ubiquitin MYC and the pCDNA3-Cul1 were generous gifts of Drs A Holloway and A Pause respectively. For tagging of cyclin D1, a NotI site was introduced by site directed mutagenesis in front of the stop codon and used for the insertion of a NotI fragment containing a triple HA tag. For tagging of Cul-1, a fragment containing the triple HA tag¯anked by a KpnI and BamHI sites was ampli®ed by PCR and inserted in frame with the Cul-1 gene in the pCDNA3-Cul-1 plasmid. Transfection in U2OS was performed by lipofection using the FuGENE TM 6 system as described by the manufacturer (Boehringer Mannheim).
Protein extractions, immunoprecipitation and Western blotting
For protein extractions from cancer samples, small aliquots of cancer homogenates were added to 250 ml of ice cold lysis buer (0.5 M Tris pH 6.8. 0.4% SDS, 1 mg/ml Aprotinin, 1 mg/ml Leupeptin, 1 mg/ml Pepstatin, 100 mg/ ml PMSF, 100 m/ml TPCK) and immediately sonicated for 15 ± 20 pulses on ice. Lysates were clari®ed by centrifugation at 44 000 g for 15 min at 48C and the protein concentration of the supernatant was assayed using the BCA Kit (Pierce). For crude protein extractions from the U2OS cell lines, cells were washed three times in ice cold PBS and lysed in 250 ml of lysis buer as described for the cancer samples. For immunoprecipitation, cells were lysed in 50 mM Tris pH 8.0, 150 mM NaCl, 0.5% NP40, 0.1 mM sodium¯uoride, 0.1 mM sodium orthovanadate and the lysates clari®ed by centrifugation at 13 000 r.p.m. for 20 min at 48C. The supernatant transferred to a new tube and anity puri®ed primary antibodies were added to lysates at a concentration of 0.8 mg/ml for anti-cyclin D1 and anti-cyclin D3 and 0.4 mg/ml for 12CA5. After incubation on ice for 60 min with the appropriate antibodies, 50 ml of protein A-Sepharose was added and the incubation was continued for another 60 min. The peptide aldehyde leucinyl-leucinyl-norleucinyl (LLnL) was solubilized in DMSO at a concentration of 20 mM. Cells were treated for 14 h with LLnL diluted to 100 mM or with DMSO alone. For detection of ubiquitinated cyclin D3, U2OS cells co-transfected with pCDNA3-ubiquitin MYC and pCDNA3-cyclin D3 were treated for 4 h with LLnL before protein extraction. Thirty mg of protein was diluted in SDS ± PAGE sample buer, heated for 5 min at 958C, loaded on a 12% polyacrylamide gel, transferred onto a nitrocellulose membrane, subjected to standard Western blotting analysis and developed by ECL (Amersham Life Science). For detection of cyclin D1 and cyclin D3, rabbit polyclonal antibodies M-20 and C-16 respectively (Santa Cruz) were used at a dilution of 1 : 100. For detection of actin, the monoclonal antibody N350 (Amersham Life Science) was used at a dilution of 1 : 2000. For E2F-1, Myc tagged ubiquitin, cyclin A and cyclin B1 detection mouse monoclonal antibodies (KH-95) and 9E10 and rabbit polyclonal antibodies Santa Cruz) were used at a dilution of 1 : 100.
Pulse chase labelling
Cells were washed twice in PBS at 378C and then incubated for 30 min in methionine and cysteine-free medium. Cells were labelled for either 2 h with 200 mCi/ml of Trans 35 S (NEN Corp), washed three times with PBS and refed with DMEM containing 10% FCS. At various times after termination of labelling aliquots were taken and cells lysed as described above for immunoprecipitations.
RNA extraction and RT ± PCR
RNA was extracted from cancers by the addition of a small aliquot of cancer powder to 1 ml of Trizol reagent (Gibco BRL) followed by gentle sonication (2 ± 3 pulses) on ice. Following this homogenization, RNA extraction was carried out as described by the manufacturer (Gibco BRL). 0.4 mg of total RNA was used per RT ± PCR reaction using the Titan one tube RT ± PCR system (Boehringer Mannheim). For the PCR, 30 cycles of 1 min 958C, 1 min 608C, 1 min 728C, were preceded by a step of 2 min at 958C and followed by a 5 min at 728C incubation. Primers used for cyclin D1 ampli®cations were: D1-456 (exon 3) 5'-GCC GCA ATG ACC CCG CAC GAT TTC-3' (an upstream primer representing cyclin D1 sense-strand sequences from nucleotides 456 ± 479 of the coding region) and D1-902 (exon 5) 5'-TGC CTG GGC CCC TCA GAT GTC CAC GT-3' (a downstream primer inversely complementary to 3' cyclin D1 sequences from nucleotides 902 ± 873 which¯anked the stop codon). This ampli®cation results in a fragment of 446 bp. Primers used for cyclin D3 were: D3-447 (exon 3) 5'-GCC GGG ACC TGG CTG CTG TGA TTG CAC-3' (an upstream primer representing cyclin D3 sense-strand sequences from nucleotides 447 ± 470 of the coding region) and D3-895 (exon 4) 5'-AGA GGG CCT CTC CAG GGC TAC AGG-3' (a downstream primer inversely complementary to 3' cyclin D3 sequences from nucleotides 895 ± 872 which¯anked the stop codon). This ampli®cation results in a fragment of 448 bp. Finally, primers used to amplify actin were: on the sense strand 5'-GGC ATC GTG ATG GAC TCC G-3' and on the antisense strand 5'-GCT GGA AGG TGG ACA GCG A-3' which¯anked an intron and therefore resulted in the mRNA speci®c ampli®cation of a 600 bp fragment.
Immunohistochemical staining of cancer sections
For immunostaining of paran sections, a rabbit polyclonal antibody against human cyclin D1 (Upstate Biotechnology, 06 ± 137) was used at a concentration of 1 : 400 and the monoclonal antibody DCS-22 (Oncogene Research, Ab-2) against human cyclin D3 ( Bartkova et al., 1996) was used at a dilution of 1 : 25. Immunohistochemical staining of cyclin D1 was performed on archival formalin-®xed tissue sections (3 ± 5 mm), which were dewaxed and rehydrated in water. Antigen retrieval was achieved in a pressure cooker for 2 min in 10 mM sodium citrate pH 6.0. Endogenous peroxidase activity was blocked with 3% (v/v) hydrogen peroxide for 10 min. All buer washes between antibody incubations were with 50 mM Tris-HCl pH 7.6. The cyclin D1 antibody was incubated for 30 min at room temperature and detected with the LSAB+ kit peroxidase (DAKO, K0690), with the link biotinylated anti-rabbit IgG for 15 min and streptavidin peroxidase for 15 min. Slides were developed with AEC (3-amino-9-ethyl-carbazole) chromogen (DAKO) for 15 min. Sections were then counterstained in haematoxylin for 5 s and mounted with DPX. For cyclin D3 immunostaining, antigen retrieval was performed in a Sharp Carousel (600W) microwave oven by bringing sections to boil in 10 mM sodium citrate pH 6.0 and then incubating for 20 min on medium (50%) power. Sections were blocked with 3% (v/v) hydrogen peroxide for 10 min then blocked in 10% foetal calf serum in TBS (50 mM TrisHCl, 0.9% (w/v) sodium chloride pH 7.6) for 30 min. All washes between antibody incubations were with TBS (pH 7.6). The cyclin D3 antibody was incubated at room temperature for 1 h and detected with the LSAB+ kit peroxidase. Treatment with DAB (3,3'-diaminobenzidine) chromogen for 5 min (DAKO) was used to visualize the antibody. Sections were then counterstained in haematoxylin for 5 s and mounted with DPX.
Staining assessment
Demonstration of cyclin D1 and D3 staining was assessed according to both the extent and the intensity of the staining. The extent ranges on a scale from 0 ± 5 where a score of 0 indicated less then 10% of the cells were stained, 1 for 11 ± 25%, 2 for 26 ± 50%, 3 for 51 ± 75%, 4 for 76 ± 90% and 5 for more then 90% of the cells. The intensity was scored on a scale from 0 ± 3 where 0 is negative and 3 is the strongest intensity of staining. The score for extent and intensity was then added and considered weak if the total score was between 1 ± 3, moderate between 4 ± 6 and strong when above 7. In this study, cancer sections were considered positive for cyclin D1 and D3 staining if they scored either moderate or strong.
